Cabio Biotech Valuation
| 688089 Stock | 28.83 4.49 18.45% |
At this time, the firm appears to be undervalued. Cabio Biotech Wuhan shows a prevailing Real Value of USD33.44 per share. The current price of the firm is USD28.83. Our model approximates the value of Cabio Biotech Wuhan from analyzing the firm fundamentals such as profit margin of 0.22 %, and Return On Equity of 0.0814 as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.1786 | Enterprise Value 4.7 B | Enterprise Value Ebitda 36.4889 | Price Sales 8.7425 | Trailing PE 42.3971 |
Undervalued
Today
Please note that Cabio Biotech's price fluctuation is not too volatile at this time. Calculation of the real value of Cabio Biotech Wuhan is based on 3 months time horizon. Increasing Cabio Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cabio Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cabio Stock. However, Cabio Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 28.83 | Real 33.44 | Hype 29.28 | Naive 29.5 |
The real value of Cabio Stock, also known as its intrinsic value, is the underlying worth of Cabio Biotech Wuhan Company, which is reflected in its stock price. It is based on Cabio Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cabio Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cabio Biotech Wuhan helps investors to forecast how Cabio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cabio Biotech more accurately as focusing exclusively on Cabio Biotech's fundamentals will not take into account other important factors: Cabio Biotech Cash |
|
Cabio Biotech Total Value Analysis
Cabio Biotech Wuhan is presently estimated to have takeover price of 4.71 B with market capitalization of 4.85 B, debt of 11.01 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cabio Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.71 B | 4.85 B | 11.01 M |
Cabio Biotech Investor Information
About 51.0% of the company shares are owned by insiders or employees . The book value of Cabio Biotech was presently reported as 9.07. The company last dividend was issued on the 26th of June 2024. Cabio Biotech Wuhan had 1.4:1 split on the 18th of July 2023. Cabio Biotech Wuhan is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 123.2 M | 79.2 M |
|
| |||||
| Operating Income | 96.8 M | 105.8 M |
|
|
Cabio Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cabio Biotech has an asset utilization ratio of 27.54 percent. This suggests that the Company is making USD0.28 for each dollar of assets. An increasing asset utilization means that Cabio Biotech Wuhan is more efficient with each dollar of assets it utilizes for everyday operations.Cabio Biotech Ownership Allocation
Cabio Biotech holds a total of 168.31 Million outstanding shares. Cabio Biotech Wuhan retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cabio Biotech Profitability Analysis
The company reported the revenue of 443.8 M. Net Income was 91.52 M with profit before overhead, payroll, taxes, and interest of 555.03 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cabio Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cabio Biotech and how it compares across the competition.
About Cabio Biotech Valuation
The stock valuation mechanism determines Cabio Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cabio Biotech. We calculate exposure to Cabio Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cabio Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 216.4 M | 169.2 M |
Cabio Biotech Quarterly Retained Earnings |
|
Complementary Tools for Cabio Stock analysis
When running Cabio Biotech's price analysis, check to measure Cabio Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabio Biotech is operating at the current time. Most of Cabio Biotech's value examination focuses on studying past and present price action to predict the probability of Cabio Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabio Biotech's price. Additionally, you may evaluate how the addition of Cabio Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |